Agios licenses Alnylam’s novel siRNA candidate for Polycythemia Vera
In exchange for the exclusive global right to the TMPRSS6 siRNA programme, Alnylam will receive a $17.5m upfront…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Aug 23
In exchange for the exclusive global right to the TMPRSS6 siRNA programme, Alnylam will receive a $17.5m upfront…
04 Aug 23
The expanded agreement includes the renewal of the non-exclusive total laboratory solution collaboration agreement and an eco-social collaboration…
04 Aug 23
The partnership builds upon the companies' existing collaboration, which centres around the development and commercialisation of pelacarsen
04 Aug 23
Start-up US biotech company tackling rare diseases presents three case studies in France
04 Aug 23
Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery…
03 Aug 23
The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Aug 23
The three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including…
02 Aug 23
LX2020 is an AAV-based gene therapy that works by intravenously delivering a functional PKP2 gene to increase the…
02 Aug 23
Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted…
02 Aug 23
Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates